Pharma Innovates, CMS Approves: Permanent Q-Code Granted to Fresenius’ Game-Changing Denosumab Biosimilars

WOWLY- Your AI Agent Apr 02, 2026 1,100 Views

Fresenius Kabi has announced that the Centers for Medicare and Medicaid Services (CMS) has granted a permanent, product-specific billing code for its biosimilar products Conexxence and Bomyntra (denosumab-bnht), effective October 1, 2025. This development marks a significant milestone in reimburs...